

A Case Control Assessment of Glycated Haemoglobin & Total Protein and Albumin Levels in Patients with Type 2 Diabetes Mellitus

Shailesh Kumar Pankaj¹, Sujit Kumar², Rashmi Singh³, C P Jaiswal⁴

¹Tutor, Department of Pathology, NMCH, Patna, Bihar, India

²Tutor, Department of Physiology, NMCH, Patna, Bihar, India

³Tutor, Department of Community Medicine, PMCH, Patna, Bihar, India

⁴Associate Professor, Department of Pathology, NMCH, Patna, Bihar, India

Received: 25-09-2022 / Revised: 25-10-2022 / Accepted: 28-11-2022

Corresponding author: Dr. Rashmi Singh

Conflict of interest: Nil

Abstract

Aim: To evaluate the glycated haemoglobin, total protein and albumin levels in patients with type 2 diabetes mellitus.

Material & Methods: A case control study was carried out at Department of Pathology, NMCH, Patna, Bihar, India for one year to evaluate the glycated haemoglobin, total protein and albumin levels in patients with type 2 diabetes mellitus. The protocol was explained to the subjects and those who gave their informed consent were recruited for the study. A total of 122 subjects comprising of 61 diabetic subjects and 61 controls aged between 40 and 73 years were recruited for the study.

Results: The mean level of HbA1c was significantly higher in the diabetic subjects when compared with control group (9.71 ± 1.30 Vs 5.58 ± 0.65 ; $p=0.000$). There were no significant differences observed between the age, the serum levels of Albumin and Total protein in the test and control subjects ($p>0.05$). There was no significant correlation between age, HbA1c, total protein and albumin in diabetic subjects.

Conclusion: This finding implies that there was a poor glycemic control in the diabetic subjects studied. Therefore, there is need for better management of diabetic patients through medication and use of diet and exercise.

Keywords: Glycated Haemoglobin, Albumin, Total Protein, Diabetes Mellitus (DM), Glycemic Control.

This is an Open Access article that uses a fund-ing model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/4.0>) and the Budapest Open Access Initiative (<http://www.budapestopenaccessinitiative.org/read>), which permit unrestricted use, distribution, and reproduction in any medium, provided original work is properly credited.

Introduction

Diabetes mellitus (DM) is a chronic metabolic disease which results from diminished or absent secretion of insulin or even by reduced tissue sensitivity to insulin resistance in Type 2 diabetes mellitus affects the metabolism of carbohydrates, lipids and proteins. [1] Type 2 diabetes mellitus is one of the

leading causes of preventable death in the world, with stroke, myocardial infarction and other cardiovascular diseases being the most common causes of death for adults with diabetes. [2] A number of factors including less glycemic control, smoking, high blood pressure, elevated cholesterol levels, obesity, and lack of regular exercise are

considered to be risk factors that accelerate the deleterious effects of diabetes. [3] HbA1c gives an estimate of the average blood glucose levels of the previous three months in diabetes. Protein glycation and HbA1c have been shown to be involved in long term complications of diabetes mellitus. Glycated albumin has decreased half-life due to increased catabolic rate. [4,5]

Albumin is one of the most abundant plasma proteins. The glycation of albumin to form glycated albumin (GA) is ten times more than the glycation of hemoglobin in type 2 DM. [6] GA is a marker reflects a short-term glycemic control. One advantage of utilizing serum albumin as a measure of glycemic control is its shorter half-life of 21 days, which renders its serum concentration more sensitive to recent change in average blood glucose level than HbA1C. [7] Studies have shown decreased albumin levels associated with increased HbA1c and total protein.

Protein glycation is involved in the long-term complications of diabetes. [4,8] Plasma proteins are the primary targets of glycation following elevated levels of glucose in diabetes. [9] Amongst plasma proteins, albumin is one of the heavily glycosylated proteins because of its abundance, comparatively longer half-life and a higher number of free lysine and arginine residues. [10] It has been mechanistically shown that albumin competes with other proteins for glycation [11] and low albumin level was associated with increased plasma protein glycation in diabetes. [12] It has also been suggested that low plasma albumin predicts the glycosylated hemoglobin (HbA1c) in type 2 diabetes, [13] thus, strongly implicating albumin in regulation of plasma protein glycation and HbA1c.

Therefore, the present study evaluated the glycosylated haemoglobin, total protein and albumin levels in patients with type 2

diabetes mellitus.

Material & Methods

A case control study was carried out at Department of Pathology, NMCH, Patna, Bihar, India for one year to evaluate the glycosylated haemoglobin, total protein and albumin levels in patients with type 2 diabetes mellitus. The protocol was explained to the subjects and those who gave their informed consent were recruited for the study. A total of 122 subjects comprising of 61 diabetic subjects and 61 controls aged between 40 and 73 years were recruited for the study. The patients and controls were aged and sex matched. Subsequently, structured questionnaire was used to obtain patients' biodata and thereafter, 5mls of blood sample was collected from each patient and 1ml was dispensed into EDTA for the estimation of glycosylated haemoglobin, and 4ml was dispensed into plain containers for estimation of serum albumin and total protein levels.

Inclusion criteria

Known diabetic subjects aged between 40 and 73 years were recruited for the study.

Exclusion criteria

Those younger than 40 or older than 73 years and non-diabetic subjects were excluded from the study.

Determination of glycosylated haemoglobin level

Glycosylated Haemoglobin level was determined using immunoturbidimetric method as described by Wolf *et al.*, (1984). [13]

Estimation of serum albumin level

Serum albumin level was estimated Bromo Cresol green Method as described by Doumas *et al.*, (1971). [14]

Estimation of total protein

Estimation of serum total protein level was done using Biuret Method according

to Weichsel Baum, (1946). [15]

Statistical analysis

The data were presented as mean SD and the mean values of the control and test group were compared by Students t-test and Pearson correlation using Statistical package for social sciences (SPSS) (Version 20) software. Statistical significance was tested at $P < 0.05$.

Results

The mean level of HbA1c was significantly higher in the diabetic subjects when compared with control group (9.71 ± 1.30 Vs 5.58 ± 0.65 ; $p = 0.000$). There were no significant differences observed between the age, the serum levels of Albumin and Total protein in the test and control subjects ($p > 0.05$).

Table 1: Levels of HbA1c, total protein and albumin in diabetic and control subjects

| Parameters | Control | Diabeticsubject | t- test | p- value |
|---------------|------------|-----------------|---------|----------|
| Age(years) | 54.69±7.65 | 46.71±6.02 | - 0.082 | 0.935 |
| HbA1c (%) | 4.78±0.65 | 7.89±1.30 | 1.712 | 0.000* |
| Protein (g/l) | 51.08±9.8 | 54.08±4.6 | 1.649 | 0.104 |
| Albumin (g/l) | 32.69±5.45 | 34.56±6.7 | 0.191 | 0.849 |

Table 2 shows that there is no significant correlation between age, HbA1c, total protein and albumin in diabetic subjects.

Table 2: Correlation of HbA1c with age, total protein and albumin in diabetic subjects

| Parameters | R | p-value |
|------------------------|--------|---------|
| HbA1c Vs age | 0.078 | 0.047 |
| HbA1c Vs Total protein | 0.096 | 0.571 |
| HbA1c Vs Albumin | -0.162 | 0.338 |
| Age Vs Total protein | -0.044 | 0.797 |
| Age Vs Albumin | 0.085 | 0.615 |
| Total protein Vs | -0.007 | 0.966 |

Discussion

The results of our study showed a statistically significant negative correlation between HbA1c and serum albumin levels. This persisted despite adjusting for confounding factors like FPG age, BMI, Hb, serum creatinine, serum globulin, total protein. Notably, common clinical conditions like anemia and drugs interfering with HbA1c estimations like aspirin were excluded.

In this study, the mean level of HbA1c was significantly higher in the diabetic subjects than in control. This increase can be attributed to hyperglycaemia and disturbances of carbohydrate, fat and protein metabolism that results from abnormalities in insulin secretion, insulin action or even both (IDF, 2015; ADA, 2016). [16,17] This finding implies that there is a poor glycemic control in the diabetic subjects under study.

Furthermore, our finding shows a higher mean value of HbA1c (9.71 ± 1.30) than the recommended cut- point ($< 7\%$) in diabetic patients (ADA, 2010). It follows therefore, that these patients may be at greater risk of long- term complications due to diabetes if the glycemic level is not properly controlled and this call for concern in the management of diabetic patients.

However, there was no significant difference between the mean serum level of Albumin in the test subjects when compared with control subjects ($p > 0.05$). This may be as a result of Insulin resistance which is a principal cause of type 2 diabetes (Kahn, 1994) [18] and previously, serum albumin has been associated with insulin resistance (Hostmark et al., 2005; Ishizaka et al., 2007). [19,20] In diabetic patients, plasma albumin concentration has been reported to be inversely related with HbA1c levels, revealing a large proportion of poorly

controlled diabetes in patients with lower plasma albumin concentrations (Rodriguez- Segade et al., 2005; Hemangi et al., 2012). [21,22] This inverse relationship may also be explained by the fact that poorly controlled type 2 diabetes has been associated with a further decrease in insulin production and secretion by the pancreatic β -cell (Marshak et al., 1999; Kahn, 2003). [23,24] Furthermore, our finding shows no significant difference between the serum levels of total protein in the diabetic patients and control subjects ($p>0.05$). This is in contrast with the findings of (Malawadi and Adiga, 2016; Nazki et al., 2017). [25,26]

Our study in Indian subjects suggests that higher serum albumin levels may decrease HbA1c levels and that lower serum albumin levels may raise HbA1c levels as reported previously from western studies. [22] Further, we caution that our study may be interpreted as hypothesis-generating, rather than hypothesis proving results, as this study has several limitations -importantly, it was a retrospective study. Also, we classified subjects into hyperglycemia and non hyperglycemia and did not group them into diabetes and non-diabetes. [27]

Conclusion

In conclusion, the present study showed significantly higher mean levels of HbA1c in the diabetic patients compared with the control subjects. However, the mean serum of levels of Albumin and total protein did not differ significantly when compared between the diabetic patients and controls. This finding implies that there was a poor glycemic control in the diabetic subjects studied. Therefore, there is need for better management of diabetic patients through medication and use of diet and exercise.

References

1. World Health Organization, Definition, Diagnosis and Classification of

Diabetes Mellitus and its complications. Geneva: WHO; 1999. Report of a WHO Consultation

2. Newman JD, Schwartzbard AZ, Weintraub H. Primary prevention of cardiovascular disease in diabetes mellitus. *J Am College Cardiol.* 2017; 70:883–893.
3. Raheem ME, Ahmed AM, E. Evaluation of Lipid Metabolism among Sudanese Patients with Type 2 Diabetes Mellitus. *Int J Pure Appl Sci Technol.* 2014;23(1):28–33.
4. Bourdon E, Loreau N, Blache D. Glucose and free radicals impair the antioxidant properties of serum albumin. *The FASEB journal.* 1999 Feb;13(2):233-44.
5. Shalbha Tiwari,1 Manish Bothale,2 Imtiaz Hasan,3 Mahesh J. Kulkarni, Association between serum albumin and glycated hemoglobin in Asian Indian subjects. *Indian J Endocrinol Metab.* 2015 Jan-Feb; 19(1): 52–55
6. Tahara Y, Shima K. Kinetics of HbA1c, glycated albumin, and fructosamine and analysis of their weight functions against preceding plasma glucose level. *Diabetes care.* 1995 Apr 1;18(4):440-7.
7. Yoon HJ, Lee YH, Kim KJ, Kim SR, Kang ES, Cha BS, Lee HC, Lee BW. Glycated albumin levels in patients with type 2 diabetes increase relative to HbA1c with time. *BioMed Research International.* 2015 Sep 21;2015.
8. Brownlee M. Biochemistry and molecular cell biology of diabetic complications. *Nature.* 2001 Dec 13; 414(6865):813-20.
9. Austin GE, Mullins RH, Morin LG. Non-enzymic glycation of individual plasma proteins in normoglycemic and hyperglycemic patients. *Clinical chemistry.* 1987 Dec 1;33(12):2220-4.
10. Rondeau P, Bourdon E. The glycation of albumin: structural and functional impacts. *Biochimie.* 2011 Apr 1;93(4): 645-58.

11. Bhonsle HS, Singh SK, Srivastava G, Boppana R, Kulkarni MJ. Albumin competitively inhibits glycation of less abundant proteins. *Protein and peptide letters*. 2008 Jul 1;15(7):663-7.
12. Bhonsle HS, Korwar AM, Kote SS, Golegaonkar SB, Chougale AD, Shaik ML, Dhande NL, Giri AP, Shelgikar KM, Boppana R, Kulkarni MJ. Low plasma albumin levels are associated with increased plasma protein glycation and HbA1c in diabetes. *Journal of proteome research*. 2012 Feb 3;11(2):1391-6.
13. Wolf HU, Lang W, Zander R. Alkaline haematin D-575, a new tool for the determination of haemoglobin as an alternative to the cyanhaemoglobin method. II. Standardisation of the method using pure chlorohaemin. *Clinica chimica acta*. 1984 Jan 16;136(1):95-104.
14. Dumas BT, Watson WA, Biggs HG. Albumin standards and the measurement of serum albumin with bromocresol green. *Clinica chimica acta*. 1971 Jan 1;31(1):87-96.
15. Weichselbaum CT. An accurate and rapid method for the determination of proteins in small amounts of blood serum and plasma. *American journal of clinical pathology*. 1946 Mar 1;16(3):40-9.
16. International Diabetes Federation: IDF Diabetes Atlas: International Diabetes Federation. 2017
17. International Diabetes Federation: IDF Diabetes Atlas. 7th ed. Belgium: International Diabetes Federation; 2015.
18. Kahn CR. Insulin action, diabetogenic, and the cause of type II diabetes. *Diabetes*. 1994 Aug 1;43(8):1066-85.
19. Høstmark AT, Tomten SE, Berg JE. Serum albumin and blood pressure: a population-based, cross-sectional study. *Journal of hypertension*. 2005 Apr 1;23(4):725-30.
20. Ishizaka N, Ishizaka Y, Nagai R, Toda EI, Hashimoto H, Yamakado M. Association between serum albumin, carotid atherosclerosis, and metabolic syndrome in Japanese individuals. *Atherosclerosis*. 2007 Aug 1;193(2):373-9.
21. Hemangi SB, Arvind MK, Sachin SK, Sandeep BG, Ashok DC, et al. Low Plasma Albumin Levels Are Associated with Increased Plasma Protein Glycation and HbA1c in Diabetes. *J Proteome Res*. 2012;11(2):1391–1396.
22. Rodríguez-Segade S, Rodríguez J, Mayan D, Camiña F. Plasma albumin concentration is a predictor of HbA1c among type 2 diabetic patients, independently of fasting plasma glucose and fructosamine. *Diabetes care*. 2005 Feb 1;28(2):437-9.
23. Kahn SE. The relative contributions of insulin resistance and beta-cell dysfunction to the pathophysiology of type 2 diabetes. *Diabetologia*. 2003 Jan;46:3-19.
24. Marshak S, Leibowitz G, Bertuzzi F, Succi C, Kaiser N, Gross DJ, Cerasi E, Melloul D. Impaired beta-cell functions induced by chronic exposure of cultured human pancreatic islets to high glucose. *Diabetes*. 1999 Jun 1;48(6):1230-6.
25. Malawadi BN, Adiga U. Plasma proteins in Type 2DM. *IOSR J Biotechnol Biochem*. 2016;2(5):1–03.
26. Nazki FA, Syeeda A, Mohammed S. Total proteins, albumin and HbA1c in type 2 diabetes mellitus. *Medpulse Int J Biochem*. 2017;3(3):40–42.
27. Erazo E. W. V., Walles J. G., Bejarano H. A., Ustariz R. J. M., Mejía A. O., Escobar P. L. J., Cabra O. P., & Rodriguez A. C. E. Reconstruction through the Use of the Posterior Peroneum for Coverage of Defects of the Distal Third of the Leg. *Journal of Medical Research and Health Sciences*. 2022; 5(4): 1967–1972.